Provided by Tiger Trade Technology Pte. Ltd.

Jupiter Neurosciences

2.69
-0.1500-5.28%
Volume:5K
Turnover:12.31K
Market Cap:3.55M
PE:-0.14
High:2.79
Open:2.70
Low:2.68
Close:2.84
52wk High:135.75
52wk Low:2.25
Shares:1.32M
Float Shares:1.10M
Volume Ratio:0.58
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.5676
EPS(LYR):-18.7500
ROE:-1888.70%
ROA:-159.56%
PB:-9.69
PE(LYR):-0.14

Loading ...

Jupiter Neurosciences FY26 Q2 Net Loss Widens 0.95% to $2.27 Million; Revenue Totals $24,245

Reuters
·
Aug 15

Jupiter Neurosciences Inc trading halted, news pending

TIPRANKS
·
Aug 07

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Aug 07

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

THOMSON REUTERS
·
Aug 05

Jupiter Neurosciences Raises Capital Through Equity Offering

TIPRANKS
·
Jul 29

Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering

Reuters
·
Jul 29

Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented

Reuters
·
Jul 27

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

TIPRANKS
·
Jul 23

Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement

Reuters
·
Jul 23

Jupiter Neurosciences Licenses ALA-002 for U.S. Development

TIPRANKS
·
Jul 22

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

TIPRANKS
·
Jul 22

Jupiter Neurosciences (nasdaq: Juns) Signs Definitive Agreement for Exclusive U.S. Rights to Ala-002 in Transaction Valued at up to $100 Million

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Royalty of 3% of Net Sales After Third Commercialization Milestone

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Deal Valued at up to $100 Mln Including Milestone Payments

THOMSON REUTERS
·
Jul 21

Pharmala Licenses Exclusive US Rights to Ala-002 to Jupiter Neurosciences for up to Us$100 Million

Reuters
·
Jul 21

Pharmala Biotech - to Manufacture Gmp-grade Ala-002 for Jupiter Under Separate Supply Agreement

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Development and Regulatory Milestones up to $23.33 Mln Including $20 Mln for FDA Approval

THOMSON REUTERS
·
Jul 21

Pharmala Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to Ala-002

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Upfront Payment of $3.33 Mln: $1.50 Mln Cash, $1.83 Mln in Jupiter Stock

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Deal Valued up to $100 Mln Including $3.33 Mln Upfront and Milestones Plus Royalties

THOMSON REUTERS
·
Jul 21